Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and duration of neutropenia place patients at higher risk of developing febrile neutropenia (FN) and experiencing dose reductions or delays that may compromise the efficacy of chemotherapy (Gargiulo et al, 2021). Additionally, among patients with cancer, hospitalizations related to complications of CIN result in substantial medical costs, in addition to increased morbidity and mortality (Li et al, 2020). Therefore, it is essential that members of the multidisciplinary team have a comprehensive understanding of the risk factors, current clinical practice guidelines, emerging data, and management strategies for CIN. In this activity, Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP^®, CPNP, will update clinicians on recent developments in the prevention, treatment, and management of CIN.